What it's for (Indications)
- Rasagiline is primarily indicated for the treatment of Parkinson's disease.
- It can be used as monotherapy in early-stage Parkinson's disease to improve motor symptoms and potentially delay the need for dopaminergic therapy.
- Additionally, it is approved for use as an adjunctive therapy in patients with more advanced Parkinson's disease who are already receiving levodopa.
- In this adjunctive role, rasagiline helps to reduce 'off' time (periods of poor motor control) and improve overall motor function and daily living activities.
- Its therapeutic benefits stem from its ability to enhance central dopaminergic activity, thereby alleviating the characteristic motor deficits associated with the neurodegenerative process that defines Parkinson's disease.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of rasagiline for the treatment of Parkinson's disease is 0.5 mg or 1 mg administered orally once daily. When used as monotherapy for early-stage Parkinson's disease, the typical starting and maintenance dose is 1 mg once daily. For adjunctive therapy with levodopa in advanced Parkinson's disease, either 0.5 mg or 1 mg once daily can be used, depending on individual patient response, tolerability, and the presence of co-morbidities. Rasagiline can be taken with or without food. Dosage adjustments are crucial in patients with hepatic impairment; for example, in moderate hepatic impairment, the dose should be reduced to 0.5 mg daily, and it is strictly contraindicated in severe hepatic impairment. Concomitant medications, particularly those that inhibit CYP1A2, may also necessitate careful dose consideration. |
Safety & Warnings
Common Side Effects
- Commonly reported adverse effects associated with rasagiline include headache, dizziness, nausea, dyspepsia, postural hypotension (orthostatic hypotension), arthralgia, depression, and flu syndrome.
- As an MAO-B inhibitor, more serious side effects, though less frequent, can include serotonin syndrome, especially when co-administered with certain antidepressants or other serotonergic agents.
- Other significant concerns include dyskinesia (exacerbation or new onset when used with levodopa), hallucinations, impulse control disorders (e.
- g.
- , pathological gambling, hypersexuality, compulsive shopping, binge eating), and falling asleep during activities of daily living.
- Patients should be monitored for skin changes suggestive of melanoma, given the increased risk in Parkinson's disease patients.
- Hypertension, including hypertensive crisis with certain food/drug interactions, is also a potential risk.
Serious Warnings
- Black Box Warning: Serious Warnings: Rasagiline, while a valuable treatment for Parkinson's disease, is associated with several serious risks that necessitate careful patient education and vigilant monitoring. A primary concern is the potential for a hypertensive crisis if patients consume significant amounts of tyramine-rich foods or certain sympathomimetic medications while on higher doses of rasagiline, due to its monoamine oxidase inhibitory activity. Furthermore, the co-administration of rasagiline with serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, or certain opioid analgesics (e.g., meperidine, tramadol), can precipitate a potentially life-threatening serotonin syndrome. This syndrome is characterized by mental status changes, autonomic instability, and neuromuscular abnormalities. Patients and caregivers must also be alerted to the risk of impulse control disorders (e.g., pathological gambling, hypersexuality, compulsive behaviors), new or worsening dyskinesia, and sudden onset of sleep or extreme somnolence during daily activities, which can profoundly impair the ability to drive or safely operate machinery. Regular skin examinations are recommended due to the observed increased incidence of melanoma in Parkinson's disease patients.
- Patients receiving rasagiline should be thoroughly cautioned about the risk of hypertensive crisis, particularly with higher doses or if tyramine-rich foods (e.
- g.
- , aged cheeses, cured meats, certain beers, fermented soy products) or sympathomimetic agents (e.
- g.
- , decongestants containing pseudoephedrine or phenylephrine) are consumed.
- There is a significant risk of serotonin syndrome when rasagiline is used concomitantly with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, cyclobenzaprine, St.
- John's Wort, or dextromethorphan; therefore, co-administration is generally contraindicated and requires a wash-out period.
- Impulse control disorders, including pathological gambling, increased libido, and compulsive behaviors, have been reported in patients treated with dopamine agonists and MAO-B inhibitors and require careful monitoring.
- Somnolence and sudden onset of sleep during activities of daily living have occurred, necessitating caution when operating machinery or driving.
- Melanin-containing tissues, including the eye, can bind rasagiline or its metabolites, although the long-term clinical significance of this finding is unknown.
- Regular skin examinations for melanoma should be performed.
How it Works (Mechanism of Action)
Rasagiline functions as a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. By irreversibly binding to and inactivating MAO-B enzymes predominantly in the brain, it prevents the enzymatic breakdown of dopamine in the synaptic clefts of dopaminergic neurons. This inhibition leads to increased and sustained levels of endogenous dopamine within the central nervous system, particularly in the striatum, which is a critical area for motor control. In Parkinson's disease, there is a significant deficiency of dopamine, and by preserving this neurotransmitter, rasagiline helps to alleviate the characteristic motor symptoms such as tremor, rigidity, and bradykinesia. At therapeutic doses, rasagiline has minimal MAO-A inhibitory activity, which reduces the risk of the 'cheese effect' (hypertensive crisis induced by tyramine) compared to non-selective MAO inhibitors, though dietary and drug precautions are still necessary.
Commercial Brands (Alternatives)
No other brands found for this formula.